Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group.

Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak.

Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool

Data includes:

• Date on which the death occurred
• Age group
• 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated
• 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated
• 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster

Additional notes

As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm.

As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category.

On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023.

CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags.

The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON.

“Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results.

Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts.

Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different.

Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported.

Rates for the most recent days are subject to reporting lags

All data reflects totals from 8 p.m. the previous day.

This dataset is subject to change.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

• Monthly Cumulative Percent of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses and Comparison between 2024─25 and 2023─24 Seasons, by Age Group and Jurisdiction, by Age Group and Jurisdiction

• COVID-19 vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group (https://www.cdc.gov/iis/about/)

Monthly Cumulative Percent of Persons Who Received 1+ updated 2023-24 COVID-19 Vaccination Doses by Age Group and Jurisdiction

• Estimated Number of COVID-19 vaccinations among children 6 months–17 years and adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19. (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 12+ and age 5+ denominators have been uploaded as archived tables.

Starting June 30, 2021, the dataset has been reconfigured so that all updates are appended to one dataset to make it easier for API and other interfaces. In addition, historical data has been extended back to January 5, 2021.

This dataset shows full, partial, and at least 1 dose coverage rates by zip code tabulation area (ZCTA) for the state of California. Data sources include the California Immunization Registry and the American Community Survey’s 2015-2019 5-Year data.

This is the data table for the LHJ Vaccine Equity Performance dashboard. However, this data table also includes ZTCAs that do not have a VEM score.

This dataset also includes Vaccine Equity Metric score quartiles (when applicable), which combine the Public Health Alliance of Southern California’s Healthy Places Index (HPI) measure with CDPH-derived scores to estimate factors that impact health, like income, education, and access to health care. ZTCAs range from less healthy community conditions in Quartile 1 to more healthy community conditions in Quartile 4.

The Vaccine Equity Metric is for weekly vaccination allocation and reporting purposes only. CDPH-derived quartiles should not be considered as indicative of the HPI score for these zip codes. CDPH-derived quartiles were assigned to zip codes excluded from the HPI score produced by the Public Health Alliance of Southern California due to concerns with statistical reliability and validity in populations smaller than 1,500 or where more than 50% of the population resides in a group setting.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

For some ZTCAs, vaccination coverage may exceed 100%. This may be a result of many people from outside the county coming to that ZTCA to get their vaccine and providers reporting the county of administration as the county of residence, and/or the DOF estimates of the population in that ZTCA are too low. Please note that population numbers provided by DOF are projections and so may not be accurate, especially given unprecedented shifts in population as a result of the pandemic.

Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

This dataset tracks the updates made on the dataset "Cumulative Percentage of Adults 18 Years and Older Vaccinated with the Updated 2023-24 COVID-19 Vaccine" as a repository for previous versions of the data and metadata.

This dataset tracks the updates made on the dataset "Weekly Cumulative Percentage of Adults 18 Years and Older Vaccinated with the Updated 2023-24 COVID-19 Vaccine by Jurisdiction" as a repository for previous versions of the data and metadata.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

Vaccinations in London Between 8 December 2020 and 15 September 2021 5,838,305 1st doses and 5,232,885 2nd doses have been administered to London residents. Differences in vaccine roll out between London and the Rest of England London Rest of England Priority Group Vaccinations given Percentage vaccinated Vaccinations given Percentage vaccinated Group 1 Older Adult Care Home Residents 21,883 95% 275,964 96% Older Adult Care Home Staff 29,405 85% 381,637 88% Group 2 80+ years 251,021 83% 2,368,284 93% Health Care Worker 174,944 99% 1,139,243 100%* Group 3 75 - 79 years 177,665 90% 1,796,408 99% Group 4 70 - 74 years 252,609 90% 2,454,381 97% Clinically Extremely Vulnerable 278,967 88% 1,850,485 95% Group 5 65 - 69 years 285,768 90% 2,381,250 97% Group 6 At Risk or Carer (Under 65) 983,379 78% 6,093,082 88% Younger Adult Care Home Residents 3,822 92% 30,321 93% Group 7 60 - 64 years 373,327 92% 2,748,412 98% Group 8 55 - 59 years 465,276 91% 3,152,412 97% Group 9 50 - 54 years 510,132 90% 3,141,219 95% Data as at 15 September 2021 for age based groups and as at 12 September 2021 for non-age based groups * The number who have received their first dose exceeds the latest official estimate of the population for this group There is considerable uncertainty in the population denominators used to calculate the percentage vaccinated. Comparing implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following datasets can be used to estimate vaccine uptake by age group for London: ONS 2020 mid-year estimates (MYE). This is the population estimate used for age groups throughout the rest of the analysis. Number of people ages 18 and over on the National Immunisation Management Service (NIMS) ONS Public Health Data Asset (PHDA) dataset. This is a linked dataset combining the 2011 Census, the General Practice Extraction Service (GPES) data for pandemic planning and research and the Hospital Episode Statistics (HES). This data covers a subset of the population. Vaccine roll out in London by Ethnic Group Understanding how vaccine uptake varies across different ethnic groups in London is complicated by two issues: Ethnicity information for recipients is unavailable for a very large number of the vaccinations that have been delivered. As a result, estimates of vaccine uptake by ethnic group are highly sensitive to the assumptions about and treatment of the Unknown group in calculations of rates. For vaccinations given to people aged 50 and over in London nearly 10% do not have ethnicity information available, The accuracy of available population denominators by ethnic group is limited. Because ethnicity information is not captured in official estimates of births, deaths, and migration, the available population denominators typically rely on projecting forward patterns captured in the 2011 Census. Subsequent changes to these patterns, particularly with respect to international migration, leads to increasing uncertainty in the accuracy of denominators sources as we move further away from 2011. Comparing estimated population sizes and implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following population estimates are available by Ethnic group for London:

Weekly COVID-19 Vaccination Coverage of Adults 18 Years and Older by Jurisdiction

• COVID-19 vaccination coverage among adults 18 years and older is assessed through the National Immunization Survey-Adult COVID Module, providing weekly COVID-19 vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine for adults ages 18 years and older.

This dataset tracks the updates made on the dataset "Weekly Intent for Vaccination and Cumulative Percentage of Adults 18 Years and Older Vaccinated with Updated 2023-24 COVID-19 Vaccine" as a repository for previous versions of the data and metadata.

Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Jurisdiction

• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)

Abstract copyright UK Data Service and data collection copyright owner. The COVID-19 Vaccine Opinions Survey (VOS) is a follow up to the Opinions and Lifestyle Survey (OPN) (held at the UK Data Archive under SN 8635), and questions those specifically who reported hesitancy towards the coronavirus (COVID-19) vaccine. The survey has been commissioned by the Department of Health and Social Care (DHSC) to identify changes in attitudes towards the COVID-19 vaccine, and the factors and interventions that may have influenced initially hesitant people's decision to get a vaccine. Survey content for this study has been developed in consultation with DHSC, Cabinet Office and National Health Service (NHS) England. The survey was carried out using an online survey by the Office for National Statistics. The sample was based on 4,272 adults in England who took part in the OPN (over the period 13 January to 8 August 2021), specifically those who indicated hesitancy or uncertainty towards getting or who had refused to get the COVID-19 vaccine. These respondents had previously provided consent to be re-contacted for future research. The responding sample contained 2,482 individuals, representing a 58 per cent response rate. This is a one-off survey and currently there are no plans to carry out a second wave. Main Topics:

The heading of each sub-table is the socio-demographic variable, with each column in the sub-table corresponding to a level of the variable. Each cell value contains the percentage of respondents within that level who responded positively to the vaccine acceptance question. For example, in the Gender sub-table, 73% of male participants responded positively to the vaccine acceptance question compared with 69% of female respondents. These results are based on the Gallup Panel COVID-19 Web Survey, which began fielding on March 13, 2020 (and last updated in our copy of the dataset on Feb 22, 2021) with daily random samples of the U.S. adults, aged 18 and older who are members of the Gallup Panel.

Classification of factors underlying vaccine acceptance and vaccine hesitancy or refusal.

Despite the significant success of India’s COVID-19 vaccination program, a sizeable proportion of the adult population remains unvaccinated or has received a single dose of the vaccine. Despite the recommendations of the Government of India for the two doses of the COVID-19 vaccine and the precautionary booster dose, many people were still hesitant towards the COVID-19 full vaccination. Hence, this study aimed to identify the primary behavioral and psychological factors contributing to vaccine hesitancy. Cross-sectional data was collected via a multi-stage sampling design by using a scheduled sample survey in the Gorakhpur district of Uttar Pradesh, India, between 15 July 2022 to 30 September 2022. This study has utilized three health behavior models—the Health Belief Model (HBM), the Theory of Planned Behavior (TPB), and the 5C Psychological Antecedents of vaccination, and employed bivariate and multivariable binary logistic regression model to assess the level of vaccine hesitancy and predictive health behavior of the respondents. Results indicate that among the constructs of the HBM and 5C Antecedents models, "perceived benefits", "confidence" and "collective responsibility" showed a lesser likelihood of COVID-19 vaccine hesitancy. However, in the TPB model constructs, a ‘negative attitude towards the vaccine’ showed a four times higher likelihood of COVID-19 vaccine hesitancy. From the future policy perspective, this study suggested that addressing the issue of ‘negative attitudes towards the vaccine’ and increasing the trust or confidence for the vaccine through increasing awareness about the benefits of the vaccination in India may reduce vaccine hesitancy.

Abstract

The objective of the Nigeria NLPS Phase 2 is to monitor in real-time how the Nigerian households are coping with national and global crises and their effects on the welfare and livelihoods of the households. The households in the Phase 2 are drawn from the sample of households interviewed in GHS-Panel 2018/19 including those interviewed during the Phase 1. This survey has become a flexible tool that contributes to filling critical gaps in information that could be used by the Nigerian government and stakeholders to help design policies to mitigate the negative impacts of the COVID-19 pandemic, the oil prices crises, inflation and global value chain crises, among others. The Nigeria NLPS Phase 2 is designed to accommodate the evolving nature of the crises, including revision of the questionnaire on a bi-monthly basis.

Geographic coverage

National coverage

Analysis unit

• Households
• Individuals

Kind of data

Sample survey data [ssd]

Sampling procedure

BASELINE (ROUND 1): Wave 4 of the GHS-Panel conducted in 2018/19 served as the frame for the Nigeria NLPS surveys. The GHS-Panel sample includes 4,976 households that were interviewed in the post-harvest visit of the fourth wave in January/February 2019. This sample of households is representative nationally as well as across the 6 geopolitical Zones that divide up the country. In every visit of the GHS-Panel, phone numbers are collected from interviewed households for up to 4 household members and 2 reference persons who are in close contact with the household in order to assist in locating and interviewing households who may have moved in subsequent waves of the survey. This comprehensive set of phone numbers as well as the already well-established relationship between NBS and the GHS-Panel households made this an ideal frame from which to conduct the NLPS in Nigeria.

Among the 4,976 households interviewed in the post-harvest visit of the GHS-Panel in 2019, 4,934 (99.2%) provided at least one phone number. Around 90 percent of these households (4,440) provided a phone number for at least one household member while the remaining 10 percent only provided a phone number for a reference person. For the second phase of the NLPS, all 4,440 GHS-Panel households with household member contact details were included in the sample to be contacted. This included the sample of households from the first phase of the NLPS who had household member contact details (2,701 of 3,000). Based on the response rate in the first phase of the NLPS of 65 percent, this was expected to yield an interviewed sample of nearly 2,900 households that is both nationally representative as well as representative of urban and rural areas of the country.

ROUND 2: Interviewers attempted to contact and interview all 2,922 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2. The second round of the NLPS Phase 2 also included individual-level data collection on the migration history of household members. For the migration module, information on adult (15 years or older) members of the household was targeted, including respondents that fall into this age range. However, information was not captured for all adult members. In order to limit the burden for respondents and interviewers in cases where the number of adult members is large, a maximum of 6 household members were selected (in addition to the main respondent) to capture information on migration. Therefore, for households with less than 6 adult members, all eligible members were included. However, 93 percent of interviewed households had 6 or less adult members and only 7 percent had more than six. For the 7 percent with more than 6 adult members, 6 members were randomly selected from among the pool of eligible members. The selection was stratified by sex with an equal split of 3 male and 3 females was targeted, depending on the pool of eligible males and females. However, the application of selection as relatively rare.

ROUND 3: Interviewers attempted to contact and interview all 2,811 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2, excluding 41 households that refused in Round 2. The third round of the NLPS Phase 2 also included individual-level data collection on employment and job history of household members. For the employment and job history modules, information on adult (15 years or older) members of the household was targeted, including respondents that fall into this age range. However, information was not captured for all adult members. In order to limit the burden for respondents and interviewers in cases where the number of adult members is large, a maximum of 4 household members were selected (in addition to the main respondent) to capture information on employment and job history. Therefore, for households with less than 4 adult members, all eligible members were included.

However, 90 percent of interviewed households had 4 or less adult members and only 10 percent had more than four. For the 10 percent with more than 4 adult members, 4 members were randomly selected from among the pool of eligible members. The selection was stratified by sex with an equal split of 2 male and 2 females was targeted, depending on the pool of eligible males and females. The selection of eligible household members in Round 3 was conditional to the selection conducted in Round 2 for the migration module. In that round, up to 6 household members were selected (15 years or older) to answer the migration module. However, the application of selection as relatively rare.

ROUND 4: Interviewers attempted to contact and interview all 2,852 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2, excluding 70 households that refused in previous rounds of the survey.

ROUND 5: Interviewers attempted to contact and interview 2,824 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 98 households that refused in previous rounds of the survey.

ROUND 6: Interviewers attempted to contact and interview 2,799 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 123 households that refused in previous rounds of the survey.

ROUND 7: Interviewers attempted to contact and interview 2,784 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 138 households that refused in previous rounds of the survey.

ROUND 8: Interviewers attempted to contact and interview 2,771 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 151 households that refused in previous rounds of the survey.

ROUND 9: Interviewers attempted to contact and interview 2,753 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 169 households that refused in previous rounds of the survey.

ROUND 10: Interviewers attempted to contact and interview 2,743 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 179 households that refused in previous rounds of the survey.

ROUND 11: Interviewers attempted to contact and interview 2,732 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 190 households that refused in previous rounds of the survey.

ROUND 12: Interviewers attempted to contact and interview 2,724 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 198 households that refused in previous rounds of the survey.

ROUND 13: Interviewers attempted to contact and interview 2,714 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 208 households that refused in previous rounds of the survey.

Mode of data collection

Computer Assisted Telephone Interview [cati]

Research instrument

BASELINE (ROUND 1): One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment and non-farm enterprise; and COVID-19 vaccine.

ROUND 2: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; migration; employment; and household migrants.

ROUND 3: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment; job history; and COVID-19 vaccine.

ROUND 4: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; petrol; employment; credit; and economic sentiments. While the Household Questionnaire was administered to all the sample households, economic sentiments questions were asked to only half of the sample households (randomly selected).

ROUND 5: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment; COVID-19 vaccine; economic sentiments; and farmer screening. While the Household Questionnaire was administered to all the sample households,

Logistic regression analysis for predictors of willingness to take COVID 19 vaccine.